Epinastine hydrochloride for atopic disease

Frederick W. Fraunfelder

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma. Doctors and patients can choose from a variety of antiallergy medications, testifying that no one medication will suffice to treat all symptoms and that each has a different side-effect profile. Antiallergy medications target histamine receptors, as histamine release contributes to the unpleasant symptoms of itching, tearing, runny nose and skin urticaria. The ideal antihistamine would control the symptoms of atopic disease but cause very few side effects. Traditionally, unwanted effects include drowsiness and somnolence due to CNS depression, and digestive tract problems such as loss of appetite, nausea, vomiting and constipation or diarrhea. Some antihistamines also have anticholinergic effects that are mediated by muscarinic receptors. These atropine-like actions, which can affect the cardiovascular system, are sufficiently prominent in some drugs to be manifest during clinical usage. Epinastine hydrochloride minimally penetrates the blood/brain barrier and has almost no effect on the muscarinic receptors. This drug is marketed as having very few CNS-depressant side effects, few drug interactions and gastrointestinal side effects, and a low risk of cardiotoxicity.

Original languageEnglish (US)
Pages (from-to)677-683
Number of pages7
JournalDrugs of Today
Volume40
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Histamine Antagonists
Muscarinic Receptors
Central Nervous System Depressants
Allergic Conjunctivitis
Histamine Receptors
Histamine Release
Sleep Stages
Urticaria
Cholinergic Antagonists
Appetite
Atopic Dermatitis
Constipation
Pruritus
Cardiovascular System
Drug-Related Side Effects and Adverse Reactions
Blood-Brain Barrier
Atropine
Drug Interactions
Nose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Epinastine hydrochloride for atopic disease. / Fraunfelder, Frederick W.

In: Drugs of Today, Vol. 40, No. 8, 08.2004, p. 677-683.

Research output: Contribution to journalArticle

Fraunfelder, Frederick W. / Epinastine hydrochloride for atopic disease. In: Drugs of Today. 2004 ; Vol. 40, No. 8. pp. 677-683.
@article{51bda3bcc8b24846ad592825ff67d01d,
title = "Epinastine hydrochloride for atopic disease",
abstract = "Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma. Doctors and patients can choose from a variety of antiallergy medications, testifying that no one medication will suffice to treat all symptoms and that each has a different side-effect profile. Antiallergy medications target histamine receptors, as histamine release contributes to the unpleasant symptoms of itching, tearing, runny nose and skin urticaria. The ideal antihistamine would control the symptoms of atopic disease but cause very few side effects. Traditionally, unwanted effects include drowsiness and somnolence due to CNS depression, and digestive tract problems such as loss of appetite, nausea, vomiting and constipation or diarrhea. Some antihistamines also have anticholinergic effects that are mediated by muscarinic receptors. These atropine-like actions, which can affect the cardiovascular system, are sufficiently prominent in some drugs to be manifest during clinical usage. Epinastine hydrochloride minimally penetrates the blood/brain barrier and has almost no effect on the muscarinic receptors. This drug is marketed as having very few CNS-depressant side effects, few drug interactions and gastrointestinal side effects, and a low risk of cardiotoxicity.",
author = "Fraunfelder, {Frederick W.}",
year = "2004",
month = "8",
doi = "10.1358/dot.2004.40.8.850470",
language = "English (US)",
volume = "40",
pages = "677--683",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Epinastine hydrochloride for atopic disease

AU - Fraunfelder, Frederick W.

PY - 2004/8

Y1 - 2004/8

N2 - Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma. Doctors and patients can choose from a variety of antiallergy medications, testifying that no one medication will suffice to treat all symptoms and that each has a different side-effect profile. Antiallergy medications target histamine receptors, as histamine release contributes to the unpleasant symptoms of itching, tearing, runny nose and skin urticaria. The ideal antihistamine would control the symptoms of atopic disease but cause very few side effects. Traditionally, unwanted effects include drowsiness and somnolence due to CNS depression, and digestive tract problems such as loss of appetite, nausea, vomiting and constipation or diarrhea. Some antihistamines also have anticholinergic effects that are mediated by muscarinic receptors. These atropine-like actions, which can affect the cardiovascular system, are sufficiently prominent in some drugs to be manifest during clinical usage. Epinastine hydrochloride minimally penetrates the blood/brain barrier and has almost no effect on the muscarinic receptors. This drug is marketed as having very few CNS-depressant side effects, few drug interactions and gastrointestinal side effects, and a low risk of cardiotoxicity.

AB - Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma. Doctors and patients can choose from a variety of antiallergy medications, testifying that no one medication will suffice to treat all symptoms and that each has a different side-effect profile. Antiallergy medications target histamine receptors, as histamine release contributes to the unpleasant symptoms of itching, tearing, runny nose and skin urticaria. The ideal antihistamine would control the symptoms of atopic disease but cause very few side effects. Traditionally, unwanted effects include drowsiness and somnolence due to CNS depression, and digestive tract problems such as loss of appetite, nausea, vomiting and constipation or diarrhea. Some antihistamines also have anticholinergic effects that are mediated by muscarinic receptors. These atropine-like actions, which can affect the cardiovascular system, are sufficiently prominent in some drugs to be manifest during clinical usage. Epinastine hydrochloride minimally penetrates the blood/brain barrier and has almost no effect on the muscarinic receptors. This drug is marketed as having very few CNS-depressant side effects, few drug interactions and gastrointestinal side effects, and a low risk of cardiotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=4644330528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644330528&partnerID=8YFLogxK

U2 - 10.1358/dot.2004.40.8.850470

DO - 10.1358/dot.2004.40.8.850470

M3 - Article

C2 - 15510239

AN - SCOPUS:4644330528

VL - 40

SP - 677

EP - 683

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 8

ER -